Pamidronate Disodium (Aredia®)

Common name: Pamidronate Disodium
Brand name: Aredia®
 

What is Pamidronate Disodium?

Pamidronate Disodium belongs to the bisphosphonate class of drugs that is used to treat osteoporosis (bone thinning). It works by reducing the breakdown of bone.


How is Pamidronate Disodium administered?

Pamidronate disodium is administered intravenously.
 

What are possible side effects of this treatment?

Everyone responds differently to treatments for bone metastases – some experience many side effects while others experience very few. Below are some side effects experienced by those who received pamidronate disodium. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
  • Abdominal pain
  • Bone pain
  • Difficulty sleeping
  • Headache
  • Loss of appetite
  • Nausea / vomiting
  • Weakness
 

Is Pamidronate Disodium covered in my province or territory?

Pamidronate disodium is covered by provincial drug programs in:
  • Alberta
  • British Columbia
  • Manitoba
  • Northwest Territories
  • Nunavut
  • Ontario
  • Prince Edward Island
  • Quebec
  • Saskatchewan
  • Yukon
Pamidronate Disodium is not covered by provincial drug programs in:
  • New Brunswick
  • Newfoundland & Labrador
  • Nova Scotia
 

Last Reviewed: July 2017








Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
1.5 million Canadian men over 50 now at unnecessary risk for prostate cancer

Toronto (ON) – September 26, 2019 – New findings released today in a Prostate Cancer Canada nationwide survey suggest 1.
More

$2 million invested in new prostate cancer research

Prostate Cancer Canada and Movember partner to fund ten research projects breaking new ground
More

Dream car draw a win for all Ontarians affected by prostate cancer

February 22, 2019 – TORONTO, ON – A dream came true today for Harold Mutter (ticket #19273), the lucky winner of a 2018 Acura NSX valued at more than $235,000 - the prize for Prostate Cancer Canada’s seventh Rock the Road Raffle.
More

Researchers discover common markers of tumour hypoxia across 19 cancer types

Landmark pan-cancer study analyzes mutation signatures of low oxygen in more than 8,000 tumours
More

Rock the Road Raffle returns with its most valuable car to date

A 2018 Acura NSX to be prized by Prostate Cancer Canada and TADA at the AutoShow  
More


Click here for news archive